Last reviewed · How we verify

NCT06290674

Extracorporeal Shockwave on Abdominal Adiposity and Lipid Profile

Completed NA Last updated 22 July 2024
What this trial tests

NA trial testing Extracorporeal Shockwave therapy in Obesity, Abdominal in 60 participants. Completed in 1 February 2024.

Timeline
11 September 2022
Primary endpoint
1 January 2024
1 February 2024

Quick facts

Lead sponsorCairo University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date11 September 2022
Primary completion1 January 2024
Estimated completion1 February 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 45 to 60, female only, with Obesity, Abdominal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Almost postmenopausal women store significant extra visceral adipose tissue with unexplained mechanism, yet. Postmenopausal obese women with excess abdominal obesity have raised metabolic risk of numerous cardiovascular diseases, which negatively influence health policy concern. Therefore, actual need to recommend non-invasive approach that cover this lack of quantitative knowledge in clinical management of obese postmenopausal women.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Extracorporeal Shockwave therapy

Trials testing the same drug.

Other recruiting trials for Obesity, Abdominal

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06290674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing